Literature DB >> 20422430

Standards, advances and challenges in laparoscopic total mesorectal excision.

Dimitrios H Roukos, Christos Katsios.   

Abstract

Mesh：

Year:  2010        PMID： 20422430     DOI： 10.1007/s00464-010-1064-4

Source DB:  PubMed          Journal:  Surg Endosc        ISSN： 0930-2794            Impact factor:   4.584


× No keyword cloud information.
  13 in total

1.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Authors:  Pierre Laurent-Puig; Anne Cayre; Gilles Manceau; Emmanuel Buc; Jean-Baptiste Bachet; Thierry Lecomte; Philippe Rougier; Astrid Lievre; Bruno Landi; Valérie Boige; Michel Ducreux; Marc Ychou; Fréderic Bibeau; Olivier Bouché; Julia Reid; Steven Stone; Frédérique Penault-Llorca
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

2.  Risk factors for anastomotic failure after total mesorectal excision of rectal cancer.

Authors:  K C M J Peeters; R A E M Tollenaar; C A M Marijnen; E Klein Kranenbarg; W H Steup; T Wiggers; H J Rutten; C J H van de Velde
Journal:  Br J Surg       Date:  2005-02       Impact factor: 6.939

3.  Short-term outcomes after robotic-assisted total mesorectal excision for rectal cancer.

Authors:  Minia Hellan; Casandra Anderson; Joshua D I Ellenhorn; Benjamin Paz; Alessio Pigazzi
Journal:  Ann Surg Oncol       Date:  2007-09-01       Impact factor: 5.344

4.  Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.

Authors:  J A Sanchez; L Krumroy; S Plummer; P Aung; A Merkulova; M Skacel; K L DeJulius; E Manilich; J M Church; G Casey; M F Kalady
Journal:  Br J Surg       Date:  2009-10       Impact factor: 6.939

5.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

Authors:  Susan D Richman; Matthew T Seymour; Philip Chambers; Faye Elliott; Catherine L Daly; Angela M Meade; Graham Taylor; Jennifer H Barrett; Philip Quirke
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

6.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

Review 7.  Laparoscopic resection for rectal cancer: a review.

Authors:  Jensen T C Poon; Wai Lun Law
Journal:  Ann Surg Oncol       Date:  2009-07-30       Impact factor: 5.344

8.  The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.

Authors:  Byeong Seok Sohn; Tae Won Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Yoon-Koo Kang; Hyo Suk Park; Young-Soon Na; Se Jin Jang; Jin Cheon Kim; Jung Shin Lee
Journal:  Oncology       Date:  2009-09-07       Impact factor: 2.935

9.  Full robotic left colon and rectal cancer resection: technique and early outcome.

Authors:  Fabrizio Luca; Sabine Cenciarelli; Manuela Valvo; Simonetta Pozzi; Felice Lo Faso; Davide Ravizza; Giulia Zampino; Angelica Sonzogni; Roberto Biffi
Journal:  Ann Surg Oncol       Date:  2009-02-26       Impact factor: 5.344

Review 10.  Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Authors:  Salvatore Siena; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Julia Balfour; Alberto Bardelli
Journal:  J Natl Cancer Inst       Date:  2009-09-08       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.